These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24937555)

  • 41. Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Mulder CL
    Neuropsychiatr Dis Treat; 2016; 12():269-74. PubMed ID: 26893565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compliance and convenience: do physicians and patients see depot medication differently?
    Chue P
    Acta Neuropsychiatr; 2004 Dec; 16(6):314-8. PubMed ID: 26984544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Schizophrenia: current concepts and approaches to patient care.
    Buckley PF; Foster A
    Am Health Drug Benefits; 2008 May; 1(4):13-22. PubMed ID: 25126229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Symptom control and patient adherence to treatment: key goals in the treatment of psychosis.
    Adamou M
    Psychiatry (Edgmont); 2004 Jul; 1(1):18-9. PubMed ID: 21197371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The importance of using a valid method to assess medication compliance in psychosis.
    Thakurdesai A; Menon V; Lakdawala B; Soni AB; Krishnamurthy K; Andrade C
    Indian J Psychiatry; 2017; 59(3):400-401. PubMed ID: 29085114
    [No Abstract]   [Full Text] [Related]  

  • 46. Non-adherence and its consequences: understanding the nature of relapse.
    Emsley R
    World Psychiatry; 2013 Oct; 12(3):234-5. PubMed ID: 24096786
    [No Abstract]   [Full Text] [Related]  

  • 47. Principal stratification: All-or-none versus partial compliance.
    Baker SG
    Clin Trials; 2014 Jun; 11(3):380-381. PubMed ID: 24844842
    [No Abstract]   [Full Text] [Related]  

  • 48. Compliance Consideration.
    Danridge L; Greer B
    Lab Anim (NY); 2023 Mar; 52(3):53. PubMed ID: 36864295
    [No Abstract]   [Full Text] [Related]  

  • 49. Compliance Consideration.
    Danridge L; Greer B
    Lab Anim (NY); 2023 Apr; 52(4):77. PubMed ID: 37002298
    [No Abstract]   [Full Text] [Related]  

  • 50. Compliance Consideration.
    Danridge L; Greer B
    Lab Anim (NY); 2023 May; 52(5):95. PubMed ID: 37137976
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Which aspects of long-term outcome are predicted by positive and negative symptoms in early-onset psychosis? An exploratory eight-year follow-up study.
    Remberk B; Bażyńska AK; Bronowska Z; Potocki P; Krempa-Kowalewska A; Niwiński P; Rybakowski F
    Psychopathology; 2015; 48(1):47-55. PubMed ID: 25471137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics.
    Lin CH; Chan HY; Wang FC; Hsu CC
    Ther Adv Psychopharmacol; 2022; 12():20451253221079165. PubMed ID: 35340566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
    Lähteenvuo M; Tiihonen J
    Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.
    Poloni N; Ielmini M; Caselli I; Lucca G; Gasparini A; Gasparini A; Lorenzoli G; Callegari C
    Psychopharmacol Bull; 2019 Jun; 49(2):17-27. PubMed ID: 31308579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study.
    Corigliano V; Comparelli A; Mancinelli I; Montalbani B; Lamis DA; De Carolis A; Erbuto D; Girardi P; Pompili M
    Schizophr Res Treatment; 2018; 2018():4834135. PubMed ID: 30245878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.
    Ostuzzi G; Mazzi MA; Terlizzi S; Bertolini F; Aguglia A; Bartoli F; Bortolaso P; Callegari C; Caroleo M; Carrà G; Corbo M; D'Agostino A; Gastaldon C; Lucii C; Magliocco F; Martinotti G; Nosé M; Ostinelli EG; Papola D; Piccinelli MP; Piccoli A; Purgato M; Tabacchi T; Turrini G; Ruggeri M; Barbui C;
    PLoS One; 2018; 13(8):e0201371. PubMed ID: 30071042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study.
    Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2016 Feb; 25(1):21-3. PubMed ID: 26515607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.
    Masand PS; Roca M; Turner MS; Kane JM
    Prim Care Companion J Clin Psychiatry; 2009; 11(4):147-54. PubMed ID: 19750066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Partial compliance with antipsychotics and its impact on patient outcomes.
    Narasimhan M; Un Pae C; Masand N; Masand P
    Int J Psychiatry Clin Pract; 2007; 11(2):102-11. PubMed ID: 24937555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.